Comparative Pharmacology
Head-to-head clinical analysis: KADCYLA versus TRABECTEDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADCYLA versus TRABECTEDIN.
KADCYLA vs TRABECTEDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
1.5 mg/m² intravenously over 24 hours every 3 weeks.
None Documented
None Documented
Clinical Note
moderateTrabectedin + Digoxin
"Trabectedin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrabectedin + Digitoxin
"Trabectedin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrabectedin + Deslanoside
"Trabectedin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrabectedin + Acetyldigitoxin
"Trabectedin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent